Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2023-06-06

FDA Approved: BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE DIHYDRATE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)

View source ↗

Summary

The FDA approved a supplemental application for a buprenorphine hydrochloride and naloxone hydrochloride dihydrate product from Hikma Pharmaceuticals USA Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Buprenorphine hydrochloride and naloxone hydrochloride dihydrate (buprenorphine hydrochloride and naloxone hydrochloride dihydrate)

Snippet

SUPPL AP for BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE DIHYDRATE (BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE DIHYDRATE)